Bladder Cancer Clinical Trial

Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics

Summary

The objective of this pilot cohort study is to investigate associations between CIN and changes in gut microbiome composition profiles.

View Full Description

Full Description

The long-term goal of this study is to alleviate the occurrence of CIN and to improve chemotherapy treatment outcomes. The identification of associations between CIN and chemotherapy-induced changes in gut microbiome composition profiles will increase our understanding of these mechanisms that underlie CIN. An increased understanding of the underlying mechanisms will provide targets for the development of novel interventions to help alleviate CIN.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

at least 20 years of age
last chemotherapy more than 3 years ago
scheduled to receive either moderate to highly emetogenic chemotherapy with or without targeted therapies including immunotherapies) or immunotherapies/targeted therapies alone that can lead to toxicity symptoms for example, nausea and fatigue.
Patients receiving chemotherapy and/or immunotherapy treatment at a Mayo Clinic infusion center or an infusion center outside of Mayo Clinic

Exclusion Criteria:

concurrent radiation therapy
concurrent antibiotic treatment
concurrent oncolytic virus treatment

Study is for people with:

Bladder Cancer

Estimated Enrollment:

30

Study ID:

NCT05819827

Recruitment Status:

Recruiting

Sponsor:

Mayo Clinic

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

Mayo Clinic
Scottsdale Arizona, 85259, United States More Info
Clinical Trials Referral Office
Contact
855-776-0015
[email protected]
Komal P. Singh, Ph.D., R.N.
Principal Investigator
Mayo Clinic
Jacksonville Florida, 32224, United States More Info
Clinical Trials Referral Office
Contact
855-776-0015
[email protected]
Cindy Tofthagen, Ph.D., R.N.
Principal Investigator
Mayo Clinic
Rochester Minnesota, 55905, United States More Info
Clinical Trials Referral Office
Contact
855-776-0015
[email protected]
Daniel (Dan) S. Childs, M.D.
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Estimated Enrollment:

30

Study ID:

NCT05819827

Recruitment Status:

Recruiting

Sponsor:


Mayo Clinic

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.